Targeting EZH2 methyltransferase activity in ARID1A mutated cancer cells is synthetic lethal

ARID1A, a chromatin remodeler, shows one of the highest mutation rates across many cancer types. Notably, ARID1A is mutated in over 50% of ovarian clear cell carcinomas, which currently has no effective therapy. To date, clinically applicable targeted cancer therapy based on ARID1A mutational status...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nat Med
Autors principals: Biter, Benjamin G., Aird, Katherine M., Garipov, Azat, Li, Hua, Amatangelo, Michael, Kossenkov, Andrew V., Schultz, David C., Liu, Qin, Shih, Ie-Ming, Conejo-Garcia, Jose R., Speicher, David W., Zhang, Rugang
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4352133/
https://ncbi.nlm.nih.gov/pubmed/25686104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.3799
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars